Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B

Cancer Discovery(2021)10.1158/2159-8290.cd-20-0815Source: DataRank Database

AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B is a research paper published in Cancer Discovery (2021). On theSindex it has a DataRank of 0.631. It has been cited 66 times.

N/A

0.631DataRank · unranked

Scored on demand from live citation data

Open Access66 citations

Download PDF

Cite:

Linked data & code

geo gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 5.06)OA: bronzeTopics (54)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.631

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Xufen Yu ORCID,Tiphaine Martin ORCID,Ankita Bansal ORCID,Kakit Cheung,Abigail Lubin

Live enrichment

PubMed:34301793 PMC:PMC9056008 OpenAlex:https://openalex.org/W3205242879

NCI NIH

Grant: R35CA220491

NCI NIH

Grant: P30CA196521

Leo and Julia Forchheimer Foundation Postdoc Fellowship

Grant: T32CA078207

NIH NCI

Grant: R01CA204314

NIH NCI

Grant: R01CA240362

NIH NCI

Grant: R01CA238229

NIH

Grant: 1S10OD025132-01A1

An AVANCE NEO 600 MHz NMR Spectrometer System for Structural and Chemical Biology

NCI NIH HHS

Grant: F30 CA243207

NIH HHS

Grant: S10 OD025132

National Institutes of Health

Grant: 5R01CA238229-03

Allosteric inhibitors targeting oncogenic BRAF V600E dimers

National Institutes of Health

Grant: 5R01CA240362-02

REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING

National Institutes of Health

Grant: 5R01CA204314-02

Mechanism-based strategies to target oncogenic BRAF signaling

National Institutes of Health

Grant: 3R35CA220491-02S1

PTEN and Cancer

National Institutes of Health

Grant: 1P30CA196521-01

Mouse Genetics

National Institutes of Health

Grant: 5T32CA078207-05

TRAINING PROGRAM IN CANCER BIOLOGY

FWCI

5.06

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

bronze

journalhttps://cancerdiscovery.aacrjournals.org/content/candisc/11/12/3064.full.pdf

publisherhttps://cancerdiscovery.aacrjournals.org/content/candisc/11/12/3064.full.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/11/12/3064/3151833/3064.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-20-0815

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34301793

Fields of Study

Microtubule and mitosis dynamicsPI3K/AKT/mTOR signaling in cancerProtein Degradation and Inhibitors0301 basic medicine03 medical and health sciencesAnimalsApoptosisAurora Kinase BCell Line, TumorG2 Phase Cell Cycle CheckpointsHumansMiceMutationNeoplasmsPTEN PhosphohydrolasePhosphatidylinositol 3-KinasesProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)

MeSH Terms

AnimalsHumansMutationNeoplasmsProto-Oncogene Proteins p21(ras)ApoptosisPhosphatidylinositol 3-KinasesCell Line, TumorProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseMiceG2 Phase Cell Cycle CheckpointsAurora Kinase B

Keywords

Protein kinase BKRASPI3K/AKT/mTOR pathwayPhosphorylationKinaseDegradation (telecommunications)PTENProto-Oncogene Proteins B-rafPTEN PhosphohydrolaseApoptosisG2 Phase Cell Cycle CheckpointsProto-Oncogene Proteins p21(ras)MicePhosphatidylinositol 3-KinasesCell Line, TumorNeoplasmsMutationAnimalsAurora Kinase BHumansProto-Oncogene Proteins c-akt

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer

10.6084/m9.figshare.25017833.v1figshare

Additional file 1 of USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer

10.6084/m9.figshare.25017833figshare